Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II atezolizumab monotherapy in locally advanced or metastatic urothelial bladder cancer
NL-OMON44787Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in transitional cell carcinoma (TCC) and bladder cancer (2 cohorts), sponsored by Roche. Primary endpoints: Independent Review Facility-assessed objective response rate and Investigator-assessed objective response rate by modified RECIST. Started Sep 2014; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON44787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44787.